Towards multifunctional synthetic vectors.
Recent progress on the fronts of design, formulation and delivery with synthetic vectors has increased the potential of non-viral approaches to attain therapeutic applications. However, a number of hurdles remain to be cleared. On the one hand, we have the problem of producing and formulating stable, diffusible complexes and on the other hand, we have to face the fact that in vivo delivery is probably too complex and multifaceted to be achieved successfully with a single carrier molecule in most instances. This review concentrates on this latter aspect and the design of artificial multi-component vectors aimed at providing solutions to membrane crossing, endosomal escape and navigation through the nuclear pore. In many instances the solutions proposed have been inspired by natural mechanisms exploited by bacteria and viruses. However, entirely novel chemical approaches such as monomolecular DNA condensation via detergent dimerization, or endosome disruption by osmotic swelling, are also being investigated and developed. The combination of these naturally inspired and chemically-originated approaches is bringing us continually closer to the concept of constructing an artificial virus capable of delivering viable nucleic acid-based pharmaceuticals to defined cells in vivo. This review considers the most successful current solutions to the main biological barriers to gene delivery including appropriate DNA compaction, cell targeting and entry, vacuole escape, nuclear import and in vivo delivery. In the latter section, emphasis is placed on one of the most versatile non-viral vectors currently available, linear polyethylenimine.
Demeneix
Barbara
B
UMR CNRS 5166, Evolution des Régulations Endocriniennes, Muséum National d'Histoire Naturelle, 7 rue Cuvier, F 75231 Paris 5, France. demeneix@cimrs1.mnhn.fr
Hassani
Zahra
Z
Behr
Jean-Paul
JP
D021581:Active Transport, Cell Nucleus; D000818:Animals; D002490:Central Nervous System / Q000378:metabolism; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000235:genetics; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006367:HeLa Cells; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D011094:Polyethyleneimine; D012137:Respiratory System / Q000378:metabolism
D004274:DNA, Recombinant; D011094:Polyethyleneimine